|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Eggermont AM, Kroemer G and Zitvogel L:
Immunotherapy and the concept of a clinical cure. Eur J Cancer.
49:2965–2967. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Allan CP, Turtle CJ, Mainwaring PN, Pyke C
and Hart DN: The immune response to breast cancer, and the case for
DC immunotherapy. Cytotherapy. 6:154–163. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fan Z and Zhang Q: Molecular mechanisms of
lymphocyte-mediated cytotoxicity. Cell Mol Immunol. 2:259–264.
2005.PubMed/NCBI
|
|
6
|
Reinhard G, Märten A, Kiske SM, Feil F,
Bieber T and Schmidt-Wolf IG: Generation of dendritic cell-based
vaccines for cancer therapy. Br J Cancer. 86:1529–1533. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Koski GK, Cohen PA, Roses RE, Xu S and
Czerniecki BJ: Reengineering dendritic cell-based anti-cancer
vaccines. Immunol Rev. 222:256–276. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Palucka K and Banchereau J: Human
dendritic cell subsets in vaccination. Curr Opin Immunol.
25:396–402. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gardner A and Ruffell B: Dendritic cells
and cancer immunity. Trends Immunol. 37:855–865. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sabado RL, Balan S and Bhardwaj N:
Dendritic cell-based immunotherapy. Cell Res. 27:74–95. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tomasicchio M, Semple L, Esmail A, Meldau
R, Randall P, Pooran A, Davids M, Cairncross L, Anderson D, Downs
J, et al: An autologous dendritic cell vaccine polarizes a Th-1
response which is tumoricidal to patient-derived breast cancer
cells. Cancer Immunol Immunother. 68:71–83. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin M, Liang S, Jiang F, Xu J, Zhu W, Qian
W, Hu Y, Zhou Z, Chen J, Niu L, et al: 2003-2013, a valuable study:
Autologous tumor lysate-pulsed dendritic cell immunotherapy with
cytokine-induced killer cells improves survival in stage IV breast
cancer. Immunol Lett. 183:37–43. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gelao L, Criscitiello C, Esposito A, De
Laurentiis M, Fumagalli L, Locatelli MA, Minchella I, Santangelo M,
De Placido S, Goldhirsch A and Curigliano G: Dendritic cell-based
vaccines: Clinical applications in breast cancer. Immunotherapy.
6:349–360. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cheever MA, Allison JP, Ferris AS, Finn
OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL,
Weiner LM and Matrisian LM: The prioritization of cancer antigens:
A national cancer institute pilot project for the acceleration of
translational research. Clin Cancer Res. 15:5323–5337. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Benteyn D, Heirman C, Bonehill A,
Thielemans K and Breckpot K: mRNA-based dendritic cell vaccines.
Expert Rev Vaccines. 14:161–176. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maksyutov AZ, Lopatnikova YA, Kurilin VV,
Shevchenko YA, Khantakova YN, Gavrilova EV, Maksyutov RA, Peregudov
AG, Zaytsev SA, Kozlov VA and Sennikov SV: Efficiency studies of
induced cytotoxic immune response of mononuclear cells by means of
dendritic cells transfected by polyepitopic HER2/ERBB2 constructs.
Meditsinskaya Immunol. 16:417–424. 2014. View Article : Google Scholar
|
|
17
|
Kuznetsova M, Lopatnikova J, Khantakova J,
Maksyutov R, Maksyutov A and Sennikov S: Generation of populations
of antigenspecific cytotoxic T cells using DCs transfected with DNA
construct encoding HER2/neu tumor antigen epitopes. BMC Immunol.
18:312017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Garu A, Moku G, Gulla SK and Chaudhuri A:
Genetic immunization with in vivo dendritic cell-targeting
liposomal DNA vaccine carrier induces long-lasting antitumor immune
response. Mol Ther. 24:385–397. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goyvaerts C and Breckpot K: The journey of
in vivo virus engineered dendritic cells from bench to bedside: A
bumpy road. Front Immunol. 9:20522018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shevchenko YA, Khristin AA, Falaleeva SA,
Kurilin VV, Kuznetsova MS, Sidorov SV and Sennikov SV: Phenotypic
and functional characteristics of dendritic cells and contents of
suppressor cell populations in peripheral blood of breast cancer
patients. Vopr Onkol. 62:519–523. 2016.(In Russian). PubMed/NCBI
|
|
21
|
Thanendrarajan S, Nowak M, Abken H and
Schmidt-Wolf IG: Combining cytokine-induced killer cells with
vaccination in cancer immunotherapy: More than one plus one? Leuk
Res. 35:1136–1142. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gao D, Li C, Xie X, Zhao P, Wei X, Sun W,
Liu HC, Alexandrou AT, Jones J, Zhao R and Li JJ: Autologous tumor
lysate-pulsed dendritic cell immunotherapy with cytokine-induced
killer cells improves survival in gastric and colorectal cancer
patients. PLoS One. 9:e938862014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Novick D, Kim S, Kaplanski G and Dinarello
CA: Interleukin-18, more than a Th1 cytokine. Semin Immunol.
25:439–448. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wawrocki S, Druszczynska M,
Kowalewicz-Kulbat M and Rudnicka W: Interleukin-18 (IL-18) as a
target for immune intervention. ActaBiochim Pol. 63:59–63.
2016.
|
|
25
|
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5×11.pdf
|
|
26
|
WHO Handbook for Reporting the Results of
Cancer Treatment//World Health Organization 1979. Geneva: WHO
Offset Publication. No. 48. https://apps.who.int/iris/handle/10665/37200
|
|
27
|
Huang A, Zhang B, Wang B, Zhang F, Fan KX
and Guo YJ: Increased CD14(+)HLA-DR (−/low)
myeloid-derived suppressor cells correlate with extrathoracic
metastasis and poor response to chemotherapy in non-small cell lung
cancer patients. Cancer Immunol Immunother. 62:1439–1451. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sennikov SV, Shevchenko JA, Kurilin VV,
Khantakova JN, Lopatnikova JA, Gavrilova EV, Maksyutov RA, Bakulina
AY, Sidorov SV, Khristin AA and Maksyutov AZ: Induction of an
antitumor response using dendritic cells transfected with DNA
constructs encoding the HLA-A*02: 01-restricted epitopes of
tumor-associated antigens in culture of mononuclear cells of breast
cancer patients. Immunol Res. 64:171–180. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shevchenko YA, Khantakova YN, Kurilin VV,
Lopatnikova YA, Sidorov SV, Kozlov VA and Sennikov SV: Stimulation
of the cytotoxic immune response in the culture of mononuclear
cells of patients breast cancer by dendritic cells loaded with
antigens of tumor lysates. Immunology. 134:327–330. 2013.
|
|
30
|
Jeras M, Bergant M and Repnik U: In vitro
preparation and functional assessment of human monocyte-derived
dendritic cells-potential antigen-specific modulators of in vivo
immune responses. Transpl Immunol. 14:231–244. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Elizalde PV, Cordo Russo RI, Chervo MF and
Schillaci R: ErbB-2 nuclear function in breast cancer growth,
metastasis and resistance to therapy. Endocr Relat Cancer.
23:T243–T257. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Boudreau J, Bonehill A, Thielemans K and
Wan Y: Engineering dendritic cells to enhance cancer immunotherapy.
Mol Ther. 19:841–853. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Willimsky G and Blankenstein T: Sporadic
immunogenic tumours avoid destruction by inducing T cell tolerance.
Nature. 437:141–146. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bernhard H, Neudorfer J, Gebhard K, Conrad
H, Hermann C, Nährig J, Fend F, Weber W, Busch DH and Peschel C:
Adoptive transfer of autologous, HER2-specific, cytotoxic T
lymphocytes for the treatment of HER2-overexpressing breast cancer.
Cancer Immunol Immunother. 57:271–280. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Duffy MJ, Harbeck N, Nap M, Molina R,
Nicolini A, Senkus E and Cardoso F: Clinical use of biomarkers in
breast cancer: Updated guidelines from the European Group on Tumor
Markers (EGTM). Eur J Cancer. 75:284–298. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhan HL, Gao X, Pu XY, Li W, Li ZJ, Zhou
XF and Qiu JG: A randomized controlled trial of postoperative tumor
lysate-pulsed dendritic cells and cytokine-induced killer cells
immunotherapy in patients with localized and locally advanced renal
cell carcinoma. Chin Med J (Engl). 125:3771–3777. 2012.PubMed/NCBI
|
|
37
|
Marmé F: Immunotherapy in Breast Cancer.
Oncol Res Treat. 39:335–345. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Palucka AK, Ueno H, Connolly J,
Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J and Banchereau J:
Dendritic cells loaded with killed allogeneic melanoma cells can
induce objective clinical responses and MART-1 specific
CD8+ T-cell immunity. J Immunother. 29:545–557. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lowenfeld L, Mick R, Datta J, Xu S,
Fitzpatrick E, Fisher CS, Fox KR, DeMichele A, Zhang PJ, Weinstein
SP, et al: Dendritic cell vaccination enhances immune responses and
induces regression of HER2(pos) DCIS independent of route: Results
of randomized selection design trial. Clin Cancer Res.
23:2961–2971. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kuznetsova M, Lopatnikova J, Shevchenko J,
Silkov A, Maksyutov A and Sennikov S: Cytotoxic activity and memory
T cell subset distribution of in vitro-stimulated CD8+ T
cells specific for HER2/neu epitopes. Front Immunol. 10:10172019.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nishikawa H and Sakaguchi S: Regulatory T
cells in cancer immunotherapy. Curr Opin Immunol. 27:1–7. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nishikawa H and Sakaguchi S: Regulatory T
cells in tumor immunity. Int J Cancer. 127:759–767. 2010.PubMed/NCBI
|
